Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01822132
Recruitment Status : Completed
First Posted : April 2, 2013
Results First Posted : February 6, 2019
Last Update Posted : March 5, 2019
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
P. Todd Korthuis, MD, Oregon Health and Science University

Tracking Information
First Submitted Date  ICMJE March 21, 2013
First Posted Date  ICMJE April 2, 2013
Results First Submitted Date  ICMJE September 20, 2017
Results First Posted Date  ICMJE February 6, 2019
Last Update Posted Date March 5, 2019
Study Start Date  ICMJE May 2013
Actual Primary Completion Date March 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 12, 2019)
  • Discounting Tasks: Sexual Probability Discounting (SexPD) [ Time Frame: 28 days post drug intervention ]
    In the SexPD task, subjects are asked to choose between having sex with a more appealing partner with a varying chance of having a sexually transmitted infection (STI) or a less appealing partner with no STI. A hyperbolic decay model was used to calculate h, a free parameter that indexes the rate of probabilistic discounting. Smaller h values indicate a preference for probabilistic (i.e., riskier) outcomes. To normalize the data, the natural log of h values were calculated and reported here.
  • Discounting Tasks: Standard Delay Discounting (DD) [ Time Frame: 28 days post drug intervention ]
    Monetary delay discounting task consisted of choosing between a larger, delayed and a smaller, immediate reward. A hyperbolic decay model was used to calculate k, a free parameter that indexes the rate of delay discounting. As k values are typically skewed across subjects, the distribution of k was normalized by using a natural log transformation. The normalized values are reported here. If k typically ranges between 0.5 and 10^-5, then the natural log of k will range between -0.69 and -11.5. Larger normalized k values indicate a preference for smaller sooner outcomes (i.e., more impulsive decision-making).
  • Barrat Impulsiveness Scale (BIS) [ Time Frame: 28 days post drug intervention ]
    The Barrat Impulsiveness Scale (BIS) is a 30 item questionnaire to measure a persons impulsiveness. Items are answered on a 4-point scale and scored 1-4 then summed across responses. Total scores range from 30-120 with a higher summed score indicating higher impulsivity.
  • Risk Assessment Battery (RAB) [ Time Frame: 28 days post drug intervention ]
    The Risk Assessment Battery (RAB) is a 26 question self-administered assessment focusing on drug use, injection and sexual risk during the past 30 days. Three composite HIV risk scores (drug, sex, and total score) are calculated. The questions have different numbers of items, and scores for a single question can range from 0 to 7, with higher values reflecting more instances of risk behavior. The drug risk score has a range of 0 to 22 and is calculated from 8 questions that address recent substance use, including frequency, needle sharing, and cleaning of the "works." 9 questions are used to calculate a sex risk score that has a range of 0 to 18, and these questions address the frequency and types of sexual behavior, HIV status of sexual partners, and type of protection that was used (if any). Total score is calculated by adding drug and sex scores and dividing by 40, the maximum score possible, and ranges from 0 to 40 where higher scores indicate greater risk behavior.
Original Primary Outcome Measures  ICMJE
 (submitted: March 27, 2013)
Discounting Tasks [ Time Frame: 28 days ]
Delay Discounting economic task that asks subjects to choose between an immediate reward and a second reward that varies in delay until receipt. Probes the neural mechanism of the effect of endogenous opioid blockade on impulsive choice in MA users.
Change History Complete list of historical versions of study NCT01822132 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 16, 2019)
Methamphetamine Use [ Time Frame: 28 days post drug intervention ]
Participants were asked "How many days in the past 30 days did you use methamphetamine?". This is a self-report measure.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 27, 2013)
  • Neural Mapping [ Time Frame: 28 days ]
    We expect to identify a map of regions for each component of delay discounting: delay magnitude, reward magnitude and choice. Our preliminary assignment of delay sensitivity to middle frontal gyrus may reflect magnitude sensitivity. This would suggest that discounting (calculation of the value of a delayed reward) is a separate cognitive function from representation of the magnitude of the alternative reward. We expect increased ventrolateral prefrontal and ventral striatal activity with increased immediate reward magnitude in the overall group. We expect increased medial prefrontal activity to scale with decreased delay magnitude, and for dorsal regions (inferior parietal lobule, insula, and dorsolateral prefrontal cortex) to exhibit more activity in Decision trials than No Decision trials.
  • Methamphetamine Use [ Time Frame: 28 days ]
    Any methamphetamine use in the 28 days since injection of study drug or placebo, by self report and urine drug screen.
  • HIV risk behaviors [ Time Frame: 28 days ]
    Unprotected sex or sharing of needles/works in the 28 days since injection of study drug or placebo.
  • Antiretroviral adherence [ Time Frame: 28 days ]
    Any missed doses of antiretroviral medications in 28 days since injection of study drug or placebo, by self-report.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
Official Title  ICMJE Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
Brief Summary

The purpose of this protocol is to learn more about impulsive decision making in people who use methamphetamines. The investigators would like to know if a medication called naltrexone changes how people make decisions. The investigators would also like to know whether changes in decision making can be observed by MRI (magnetic resonance imaging).

The research is conducted in Portland, OR.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Other
Condition  ICMJE
  • Methamphetamine Abuse
  • HIV
Intervention  ICMJE
  • Drug: Extended release naltrexone
    Other Name: Vivitrol
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: Extended release naltrexone
    One dose of intramuscular injection of 380mg extended-release naltrexone.
    Intervention: Drug: Extended release naltrexone
  • Placebo Comparator: Placebo
    One dose of intramuscular injection of placebo.
    Intervention: Drug: Placebo
Publications * Kohno M, Dennis LE, McCready H, Schwartz DL, Hoffman WF, Korthuis PT. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend. 2018 Nov 1;192:186-192. doi: 10.1016/j.drugalcdep.2018.07.045. Epub 2018 Sep 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 16, 2019)
76
Original Estimated Enrollment  ICMJE
 (submitted: March 27, 2013)
50
Actual Study Completion Date  ICMJE March 2015
Actual Primary Completion Date March 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Summary Inclusion Criteria:

  • Diagnostic and Statistical Manual (DSM)-IV Methamphetamine Dependence
  • Deemed healthy enough to participate by study physician
  • Age 18-55
  • Right handed
  • English-speaking

Summary Exclusion Criteria:

  • Current opioid use in the last 30 days; opioid abuse or dependence within past 5 years
  • Pregnancy
  • MRI contraindications (e.g. metal in head).

The research is conducted in Portland, OR.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01822132
Other Study ID Numbers  ICMJE ALKIIT-KOR-034
1R21DA033182-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party P. Todd Korthuis, MD, Oregon Health and Science University
Study Sponsor  ICMJE Oregon Health and Science University
Collaborators  ICMJE National Institute on Drug Abuse (NIDA)
Investigators  ICMJE
Principal Investigator: Philip T Korthuis, MD, MPH Oregon Health and Science University
PRS Account Oregon Health and Science University
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP